Orphan Drug Exclusivity (ODE): The Seven-Year Monopoly The Orphan Drug Act grants seven years of market exclusivity to drugs treating rare diseases, defined as conditions affecting fewer than 200,000 patients in the United States
Supporting that upstream environment may be one of the most meaningful steps you can take for long-term metabolic health, whether you are currently on GLP-1 therapy or simply looking to strengthen the natural systems that keep your body in balance
Small intestinal bacterial overgrowth: Roles of antibiotics, prebiotics, and probiotics
If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you
Mechanisms of degradation of insoluble dietary fiber from coconut chips by ultra-high pressure
doi: 10.3389/fendo.2022.821113 Received 23 November 2021 Accepted 07 February 2022 Published 20 April 2022 Volume 13 - 2022 Edited by Paolo Moghetti, University of Verona, Italy Reviewed by Antonio Aversa, University of Catanzaro, Italy Updates Copyright 2022 Pelusi